Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BAX
stocks logo

BAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.82B
+2.57%
0.535
-7.79%
2.64B
+0.41%
0.498
-9.38%
2.84B
+1.05%
0.568
+5.1%
Estimates Revision
The market is revising Downward the revenue expectations for Baxter International Inc. (BAX) for FY2025, with the revenue forecasts being adjusted by -2.09% over the past three months. During the same period, the stock price has changed by -24.32%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.09%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.22%
In Past 3 Month
Stock Price
Go Down
down Image
-24.32%
In Past 3 Month
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 23.67 USD with a low forecast of 19.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 23.67 USD with a low forecast of 19.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
7 Hold
1 Sell
Hold
Current: 18.480
sliders
Low
19.00
Averages
23.67
High
36.00
Current: 18.480
sliders
Low
19.00
Averages
23.67
High
36.00
Morgan Stanley
Patrick Wood
Underweight
downgrade
$19 -> $15
2025-12-02
New
Reason
Morgan Stanley
Patrick Wood
Price Target
$19 -> $15
2025-12-02
New
downgrade
Underweight
Reason
Morgan Stanley analyst Patrick Wood lowered the firm's price target on Baxter to $15 from $19 and keeps an Underweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Goldman Sachs
David Roman
Neutral
downgrade
$25 -> $22
2025-10-31
Reason
Goldman Sachs
David Roman
Price Target
$25 -> $22
2025-10-31
downgrade
Neutral
Reason
Goldman Sachs analyst David Roman lowered the firm's price target on Baxter to $22 from $25 and keeps a Neutral rating on the shares. Total sales of $2.84B came in slightly below guidance and consensus, with shortfalls across all segments, most notably in MPT and Pharma, the analyst tells investors in a research note. Gross margins declined sharply to 39.4%, pressured by manufacturing variances expected to persist into 4Q25 and early 2026, though lower R&D and SG&A spending partially offset the impact. Management reduced FY25 organic growth and EPS guidance to 1%-2% and $2.35-$2.40, respectively, implying near-term softness and limited visibility into 2026, where earnings headwinds are expected to outweigh tailwinds, the firm says.
Argus
Steve Silver
Buy
to
Hold
downgrade
2025-10-31
Reason
Argus
Steve Silver
Price Target
2025-10-31
downgrade
Buy
to
Hold
Reason
Argus analyst Steve Silver downgraded Baxter to Hold from Buy.
Argus
Buy
to
Hold
downgrade
2025-10-31
Reason
Argus
Price Target
2025-10-31
downgrade
Buy
to
Hold
Reason
As previously reported, Argus downgraded Baxter to Hold from Buy. The company announced a significant dividend cut to $0.04 per share, from $0.68, aimed at improving cash flow by around $300M, the analyst tells investors in a research note. Combined with a sustained weak near-term outlook due to its pause in shipments of its Novum infusion pumps and a cautious outlook for its IV fluid solutions business, the firm anticipates that Baxter's recovery under new CEO Andrew Hider will take longer than previously expected, Argus added.
Citi
Joanne Wuensch
Neutral
downgrade
$26 -> $21
2025-10-31
Reason
Citi
Joanne Wuensch
Price Target
$26 -> $21
2025-10-31
downgrade
Neutral
Reason
Citi analyst Joanne Wuensch lowered the firm's price target on Baxter to $21 from $26 and keeps a Neutral rating on the shares.
UBS
Danielle Antalffy
Neutral
downgrade
$24 -> $21
2025-10-31
Reason
UBS
Danielle Antalffy
Price Target
$24 -> $21
2025-10-31
downgrade
Neutral
Reason
UBS analyst Danielle Antalffy lowered the firm's price target on Baxter to $21 from $24 and keeps a Neutral rating on the shares. Baxter delivered a Q3 sales miss vs. consensus across all businesses excluding Advanced Surgery and also cut its quarterly dividend, the analyst tells investors in a research note. Consensus numbers for 2026 will likely have to come down, and sales growth in 2026 might be tough to come by, the firm says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Baxter International Inc (BAX.N) is 8.40, compared to its 5-year average forward P/E of 15.86. For a more detailed relative valuation and DCF analysis to assess Baxter International Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
15.86
Current PE
8.40
Overvalued PE
20.13
Undervalued PE
11.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.07
Undervalued EV/EBITDA
10.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.88
Current PS
0.00
Overvalued PS
2.64
Undervalued PS
1.11
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BAX News & Events

Events Timeline

(ET)
2025-10-30
08:10:30
Baxter revises FY25 adjusted EPS forecast down to $2.35-$2.40, previously $2.42-$2.53
select
2025-10-30
08:08:44
Baxter projects Q4 adjusted EPS between 52c and 57c, below consensus estimate of 70c.
select
2025-10-30
08:07:53
Baxter announces Q3 adjusted earnings per share of 69 cents, surpassing consensus estimate of 60 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
05:30 AMBusinesswire
PinnedBaxter International Plans $600 Million Tender Offer for 2027 Notes
  • Tender Offer Announcement: Baxter International has announced a cash tender offer of up to $600 million for its 2027 Notes, aimed at optimizing its capital structure and reducing financial costs, thereby enhancing the company's financial flexibility.
  • Bond Details: The offer includes the 1.915% senior unsecured notes, with a maximum tender cap of $600 million, indicating the company's focus on debt management and expected to boost investor confidence.
  • Early Settlement: The company plans to conduct early settlement on December 8, 2025, with holders receiving accrued interest, further enhancing the attractiveness for investors and promoting liquidity.
  • Market Response: Given that the demand for the 2027 Notes exceeds the cap, acceptance will be on a pro-rata basis, reflecting strong market demand for Baxter's debt instruments, which could positively influence the company's future financing strategies.
[object Object]
Preview
7.0
07:22 AMGlobenewswire
James Hardie Faces Class Action Over 12% Sales Decline Amid Weak Demand
  • Demand Decline Warning: On August 19, 2025, James Hardie revealed a 12% sales decline in its North America Fiber Cement segment, primarily due to distributor inventory destocking, which the company was aware of as early as April and May, resulting in a 34% drop in share price following the announcement.
  • False Statement Allegations: The lawsuit alleges that throughout the class period, the company failed to disclose the true state of weakening demand, falsely claiming that demand remained strong and inventory levels were 'normal', causing significant losses for investors.
  • Legal Consequences: Investors must petition to serve as lead plaintiffs by December 23, 2025, indicating a severe loss of trust in the company's management, which may lead to difficulties in future financing.
  • Market Reaction: The dual impact of declining sales and legal actions has tarnished James Hardie's market image, potentially affecting its competitiveness and future growth prospects in the North American market.
[object Object]
Preview
7.0
07:21 AMGlobenewswire
James Hardie Faces Class Action Over 12% Sales Decline Amid Weak Demand
  • Demand Decline: On August 19, 2025, James Hardie revealed a 12% sales decline in its North America Fiber Cement segment due to distributor inventory destocking, indicating the company's failure to disclose the true market demand situation, which has eroded investor confidence.
  • Stock Price Plunge: Following the announcement of the sales decline, James Hardie's share price dropped over 34%, directly impacting shareholder value and reflecting significant missteps in the company's transparency regarding market conditions.
  • Increased Legal Risks: The failure to disclose critical market information has led to a class action lawsuit against James Hardie, with investors potentially able to petition to serve as lead plaintiff by December 23, 2025, heightening the company's legal and financial risks.
  • Crisis of Market Trust: This incident not only affects James Hardie's short-term stock performance but may also have long-term repercussions on its brand image and market trust, compelling the company to reassess its information disclosure policies.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Baxter International Inc (BAX) stock price today?

The current price of BAX is 18.48 USD — it has decreased -2.17 % in the last trading day.

arrow icon

What is Baxter International Inc (BAX)'s business?

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

arrow icon

What is the price predicton of BAX Stock?

Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 23.67 USD with a low forecast of 19.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Baxter International Inc (BAX)'s revenue for the last quarter?

Baxter International Inc revenue for the last quarter amounts to 2.84B USD, increased 5.04 % YoY.

arrow icon

What is Baxter International Inc (BAX)'s earnings per share (EPS) for the last quarter?

Baxter International Inc. EPS for the last quarter amounts to -0.09 USD, decreased -133.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Baxter International Inc (BAX)'s fundamentals?

The market is revising Downward the revenue expectations for Baxter International Inc. (BAX) for FY2025, with the revenue forecasts being adjusted by -2.09% over the past three months. During the same period, the stock price has changed by -24.32%.
arrow icon

How many employees does Baxter International Inc (BAX). have?

Baxter International Inc (BAX) has 38000 emplpoyees as of December 05 2025.

arrow icon

What is Baxter International Inc (BAX) market cap?

Today BAX has the market capitalization of 9.50B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free